EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps

Marisa Dorling, Juan C Hernaiz-Leonardo iD, Athenea Pascual, Arif Janjua, Andrew Thamboo iD, Amin Javer iD

The Laryngoscope · 2024-07 · 134 (7) · 3054-3059

DOI: 10.1002/lary.31305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 05.02.2024. Verfasst von Marisa Dorling und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Rhinitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the frequency and nature of adverse events related to type 2 biologic use in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), including dupilumab and mepolizumab.

Methods

This is a single‐institution retrospective study of real‐world patient data. Patients were included if they have a diagnosis of CRSwNP, have undergone at least one endoscopic sinus surgery, and have taken at least two doses of dupilumab or mepolizumab between January 1, 2016, and July 1, 2023. Data collected include clinicodemographic information and past medical/surgical history. The primary outcomes are the incidence and types of adverse events. Adjusted odds ratio was calculated to compare the biologics using logistic regression. Risk factors for developing adverse events were investigated.

Results

Eighty‐seven patients on dupilumab and 51 patients on mepolizumab were included. Thirty‐nine (45%) and 10 (20%) patients respectively encountered adverse events, which differed from phase 3 trial data. The adjusted odds ratio for adverse event rates between these two treatment groups was 3.8 (95% CI, 1.5–10.5). The most common adverse events for dupilumab were arthralgia (16%), rash (14%), and conjunctivitis or xerophthalmia (10%). The main adverse events for mepolizumab were headache (6%) and fatigue (6%). Seven dupilumab and three mepolizumab patients discontinued therapy due to adverse events. The average duration of treatment was 22.5 (range: 1–77) months for mepolizumab and 15.9 (range: 1–35) months for dupilumab.

Conclusion

Dupilumab and mepolizumab have distinct adverse event profiles. This study contributes to informing clinicians' decisions regarding the use of type 2 biologics in CRSwNP patients. Level of Evidence 3 Laryngoscope , 134:3054–3059, 2024

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasal PolypsSinusitisRhinitisAntibodies, Monoclonal, HumanizedHumansFemaleMaleRetrospective StudiesChronic DiseaseMiddle AgedAdultRisk FactorsAgedIncidenceRhinosinusitis

Stichwörter der Autor:innen

adverse eventsantibodiesdupilumabmepolizumabmonoclonalsinusitis

Substanzen

Antibodies, Monoclonal, Humanizeddupilumabmepolizumab

Autor:innen und Institutionen

  • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Otolaryngology-Head and Neck Surgery, University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: Juan C Hernaiz-Leonardo, Andrew Thamboo, Amin Javer

Zitieren

APA

Dorling, M., Hernaiz-Leonardo, J. C., Pascual, A., Janjua, A., Thamboo, A., & Javer, A. (2024). Real‐World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps. The Laryngoscope, 134(7), 3054-3059. https://doi.org/10.1002/lary.31305

Vancouver

Dorling M, Hernaiz-Leonardo JC, Pascual A, Janjua A, Thamboo A, Javer A. Real‐World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps. The Laryngoscope. 2024;134(7):3054-3059. doi:10.1002/lary.31305

BibTeX
@article{Dorling2024,
  author = {Dorling, Marisa and Hernaiz-Leonardo, Juan C and Pascual, Athenea and Janjua, Arif and Thamboo, Andrew and Javer, Amin},
  title = {Real‐World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps},
  journal = {The Laryngoscope},
  year = {2024},
  volume = {134},
  number = {7},
  pages = {3054--3059},
  doi = {10.1002/lary.31305}
}
Kostenlos starten →